Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025BloodOpen Access

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

View Full Paper
Ask AI
Bookmark
Share

Authors

OAOthman Al‐SawafMFMoritz FürstenauAGAdam Giza

Discussion

Loading...

Member takes

Overview

Observational analysis finds that fitness levels and dose intensity influence outcomes in CLL patients, suggesting a nuanced approach to therapy.

Key Points

  • Overall response rate was 89.5% in unfit patients compared to 96.1% in fit patients, highlighting fitness impact.
  • Undetectable minimal residual disease rates were 80.3% for unfit and 85.1% for fit individuals, indicating therapy effectiveness.
  • Venetoclax dose reductions occurred more often in unfit patients at 39.6%, correlating with lower outcomes.
  • The 3-year overall survival rate was 91.8% for unfit and 96.9% for fit patients, underscoring the need for tailored treatments.

Cite This Study

Al‐Sawaf et al. (2025) studied this question.

synapsesocial.com/papers/68c2384fb210217d64776b90https://doi.org/10.1182/blood.2025028899
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL – real-life data analysis of the Polish Adult leukemia group2025 · 3 citations
  2. 2Venetoclax-obinutuzumab in frontline and R/R CLL: Outcomes compared to age- and sex-matched general population2025
  3. 3Long term follow-up and results of retreatement after obinutuzumab-venetoclax in first-line CLL patients with coexisting conditions2025
  4. 4Updated results from a Phase II study of minimal residual disease-guided venetoclax + obinutuzumab for the initial treatment of fit patients with chronic lymphocytic leukemia2025 · 1 citations
  5. 5Comparison of infections in patients with chronic lymphocytic leukemia (CLL) treated with BTKi versus venetoclax obinutuzumab in first line therapy2025